Central Nervous System Agents and Erectile Dysfunction

Urologic Clinics of North America

Volumn 38, Issue 2, 2011, Pages 165-173

  Kumar, Rajeev ^a   Nehra, Ajay ^b  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^b DEPARTMENT OF UROLOGY   (United States)

Author keywords

Apomorphine; Central agents; Erectile dysfunction; Melanocortin; Serotonin

Indexed keywords

ADRENERGIC RECEPTOR BLOCKING AGENT; AGENTS ACTING ON THE GENITAL SYSTEM; AMFEBUTAMONE; AMINO ACID DERIVATIVE; APOMORPHINE; ARGININE GLUTAMATE; BREMELANOTIDE; CENTRAL NERVOUS SYSTEM AGENTS; MELANOCORTIN; MELANOCORTIN II; N METHYL DEXTRO ASPARTIC ACID; NITRIC OXIDE; PHENTOLAMINE; PHENTOLAMINE MESYLATE; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; SEROTONIN; SILDENAFIL; TRAZODONE; UNCLASSIFIED DRUG; YOHIMBINE;

DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MECHANISM; DRUG PENETRATION; DRUG POTENTIATION; DRUG TREATMENT FAILURE; ERECTILE DYSFUNCTION; HUMAN; LOW DRUG DOSE; NAUSEA; NONHUMAN; PENIS ERECTION; PRIORITY JOURNAL; REVIEW; THERAPY EFFECT; TREATMENT RESPONSE;

ALPHA-MSH; AMINO ACIDS; APOMORPHINE; CENTRAL NERVOUS SYSTEM AGENTS; DOPAMINE AGONISTS; ERECTILE DYSFUNCTION; HUMANS; MALE; MELANOCORTINS; NITRIC OXIDE; PENILE ERECTION; PEPTIDES, CYCLIC; PHOSPHODIESTERASE 5 INHIBITORS; SEROTONIN UPTAKE INHIBITORS;

EID: 79957486307     PISSN: 00940143     EISSN: 1558318X     Source Type: Journal    
DOI: 10.1016/j.ucl.2011.03.006     Document Type: Review

References (56)

1. Chuang A.T., Steers W.S. Neurophysiology of penile erection. Textbook of erectile dysfunction 1999, 59-72. Isis Medical Media, Oxford (United Kingdom). C. Carson, R. Kirby, I. Goldstein (Eds.).
2. Stoléru S., Grégoire M.C., Gérard D., et al. Neuroanatomical correlates of visually evoked sexual arousal inhuman males. Arch Sex Behav 1999, 28(1):1-21.
3. Giuliano F. Control of penile erection by the melanocortinergic system: experimental evidences and therapeutic perspectives. J Androl 2004, 25(5):683-691.
4. Dula E., Keating W., Siami P.F., et al. Efficacy and safety of fixed-dose and dose-optimization regimens of sublingual apomorphine versus placebo in men with erectile dysfunction. The Apomorphine Study Group. Urology 2000, 56(1):130-135.
5. Argiolas A., Melis M.R., Mauri A., et al. Paraventricular nucleus lesion prevents yawning and penile erection induced by apomorphine and oxytocin but not by ACTH in rats. Brain Res 1987, 421:349-352.
6. Richards N., Wayman C., Allers K.A. Electrophysiological actions of the dopamine agonist apomorphine in the paraventricular nucleus during penile erection. Neurosci Lett 2009, 465(3):242-247.
7. Mountjoy K.G., Mortrud M.T., Low M.J., et al. Localization of the melanocortin-4 receptor (MC4-R) in neuroendocrine and autonomic control circuits in the brain. Mol Endocrinol 1994, 8(10):1298-1308.
8. Van der Ploeg L.H., Martin W.J., Howard A.D., et al. A role for the melanocortin 4 receptor in sexual function. Proc Natl Acad Sci U S A 2002, 99(17):11381-11386.
9. Mizusawa H., Hedlund P., Andersson K.E. Alpha-melanocyte stimulating hormone and oxytocin induced penile erections, and intracavernous pressure increases in the rat. J Urol 2002, 167(2 Pt 1):757-760.
10. Montague D.K., Jarow J.P., Broderick G.A., et al. The management of erectile dysfunction: an AUA update. J Urol 2005, 174:230-239.
11. Hatzimouratidis K., Amar E., Eardley I., et al. Guidelines on male sexual dysfunction: erectile dysfunction and premature ejaculation. Eur Urol 2010, 57(5):804-814.
12. Lal S., Ackman D., Thavundayil J.X., et al. Effect of apomorphine, a dopamine receptor agonist, on penile tumescence in normal subjects. Prog Neuropsychopharmacol Biol Psychiatry 1984, 8(4-6):695-699.
13. Danjou P., Alexandre L., Warot D., et al. Assessment of erectogenic properties of apomorphine and yohimbine in man. Br J Clin Pharmacol 1988, 26(6):733-739.
14. Walton R.P., Lacey C. Absorption of drugs through the oral mucosa. J Pharmacol Exp Ther 1935, 54:61-76.
15. Heaton J.P., Morales A., Adams M.A., et al. Recovery of erectile function by the oral administration of apomorphine. Urology 1995, 45:200-206.
16. Lu W., Jiang W., Chen J., et al. Modulation of brain delivery and copulation by intranasal apomorphine hydrochloride. Int J Pharm 2008, 349(1-2):196-205.
17. Riley A., Main M., Morgan F. Inhalation device allows novel administration of apomorphine in men with erectile dysfunction-efficacy and safety findings. J Sex Med 2010, 7:1508-1517.
18. Porst H., Behre H.M., Jungwirth A., et al. Comparative trial of treatment satisfaction, efficacy and tolerability of sildenafil versus apomorphine in erectile dysfunction-an open, randomized cross-over study with flexible dosing. Eur J Med Res 2007, 12(2):61-67.
19. Pavone C., Curto F., Anello G., et al. Prospective, randomized, crossover comparison of sublingual apomorphine (3 mg) with oral sildenafil (50 mg) for male erectile dysfunction. J Urol 2004, 172(6 Pt 1):2347-2349.
20. Eardley I., Wright P., MacDonagh R., et al. An open-label, randomized, flexible-dose, crossover study to assess the comparative efficacy and safety of sildenafil citrate and apomorphine hydrochloride in men with erectile dysfunction. BJU Int 2004, 93:1271-1275.
21. Giammusso B., Colpi G.M., Cormio L., et al. An open-label, randomized, flexible-dose, crossover study to assess the comparative efficacy and safety of sildenafil citrate and apomorphine hydrochloride in men with erectile dysfunction. Urol Int 2008, 81(4):409-415.
22. Afif-Abdo J., Teloken C., Damião R., et al. Comparative cross-over study of sildenafil and apomorphine for treating erectile dysfunction. BJU Int 2008, 102(7):829-834.
23. Maclennan K.M., Boshier A., Wilton L.V., et al. Examination of the safety and use of apomorphine prescribed in general practice in England as a treatment for erectile dysfunction. BJU Int 2006, 98(1):125-131.
24. Wikberg J.E., Muceniece R., Mandrika I., et al. New aspects on the melanocortins and their receptors. Pharm Res 2000, 42:393-420.
25. Molinoff P.B., Shadiack A.M., Earle D., et al. PT-141: a melanocortin agonist for the treatment of sexual dysfunction. Ann N Y Acad Sci 2003, 994:96-102.
26. Sebhat I.K., Martin W.J., Ye Z., et al. Design and pharmacology of N-[(3R)-1,2,3,4-tetrahydroisoquinolinium-3-ylcarbonyl]-(1R)-1-(4-chlorobenzyl)-2-[4-cyclohexyl-4-(1H-1,2,4-triazol-1-ylmethyl)piperidin-1-yl]-2-oxoethylamine (1), a potent, selective, melanocortin subtype-4 receptor agonist. J Med Chem 2002, 45:4589-4593.
27. Hadley M.E. Discovery that a melanocortin regulates sexual functions in male and female humans. Peptides 2005, 26(10):1687-1689.
28. Dorr R.T., Lines R., Levine N., et al. Evaluation of Melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study. Life Sci 1996, 58:1777.
29. Wessells H., Fuciarelli K., Hansen J., et al. Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction (double blind placebo controlled crossover study). J Urol 1998, 160:389-393.
30. Wessells H., Gralnek D., Dorr R., et al. Effect of an alpha-melanocyte stimulating hormone analog on penile erection and sexual desire in men with organic erectile dysfunction. Urology 2000, 56:641-646.
31. Rosen R.C., Diamond L.E., Earle D.C., et al. Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to Viagra. Int J Impot Res 2004, 16(2):135-142.
32. Diamond L.E., Earle D.C., Rosen R.C., et al. Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction. Int J Impot Res 2004, 16:51-59.
33. Safarinejad M.R., Hosseini S.Y. Salvage of sildenafil failures with bremelanotide: a randomized, double-blind, placebo controlled study. J Urol 2008, 179(3):1066-1071.
34. Bitran D., Hull E.M. Pharmacological analysis of male rat sexual behavior. Neurosci Biobehav Rev 1987, 11(4):365-389.
35. Miner M.M., Seftel A.D. Centrally acting mechanisms for the treatment of male sexual dysfunction. Urol Clin North Am 2007, 34(4):483-496.
36. Andersson K.E. Pharmacology of erectile function and dysfunction. Urol Clin North Am 2001, 28(2):233-247.
37. Andersson K.E., Stief C. Oral alpha adrenoceptor blockade as a treatment of erectile dysfunction. World J Urol 2001, 19(1):9-13.
38. Goldstein I., Carson C., Rosen R., et al. Vasomax for the treatment of male erectile dysfunction. World J Urol 2001, 19(1):51-56.
39. Padma-Nathan H., Goldstein I., Klimberg I., et al. Long-term safety and efficacy of oral phentolamine mesylate (Vasomax) in men with mild to moderate erectile dysfunction. Int J Impot Res 2002, 14(4):266-270.
40. Morales A. Yohimbine in erectile dysfunction: would an orphan drug ever be properly assessed?. World J Urol 2001, 19(4):251-255.
41. Guay A.T., Spark R.F., Jacobson J., et al. Yohimbine treatment of organic erectile dysfunction in a dose-escalation trial. Int J Impot Res 2002, 14:25-31.
42. Lebret T., Hervé J.M., Gorny P., et al. Efficacy and safety of a novel combination of L-arginine glutamate and yohimbine hydrochloride: a new oral therapy for erectile dysfunction. Eur Urol 2002, 41(6):608-613. [discussion: 613].
43. Kernohan A.F., McIntyre M., Hughes D.M., et al. An oral yohimbine/L-arginine combination (NMI 861) for the treatment of male erectile dysfunction: a pharmacokinetic, pharmacodynamic and interaction study with intravenous nitroglycerine in healthy male subjects. Br J Clin Pharmacol 2005, 59(1):85-93.
44. Senbel A.M., Mostafa T. Yohimbine enhances the effect of sildenafil on erectile process in rats. Int J Impot Res 2008, 20(4):409-417.
45. Melis M.R., Argiolas A. Role of central nitric oxide in the control of penile erection and yawning. Prog Neuropsychopharmacol Biol Psychiatry 1997, 21(6):899-922.
46. Melis M.R., Stancampiano R., Argiolas A. Nitric oxide synthase inhibitors prevent N-methyl-D-aspartic acid-induced penile erection and yawning in male rats. Neurosci Lett 1994, 179(1-2):9-12.
47. Melis M.R., Argiolas A. Nitric oxide donors induce penile erection and yawning when injected in the central nervous system of male rats. Eur J Pharmacol 1995, 294(1):1-9.
48. Zheng H., Bidasee K.R., Mayhan W.G., et al. Lack of central nitric oxide triggers erectile dysfunction in diabetes. Am J Physiol Regul Integr Comp Physiol 2007, 292(3):R1158-R1164.
49. Sanna F., Succu S., Boi A., et al. Phosphodiesterase type 5 inhibitors facilitate noncontact erections in male rats: site of action in the brain and mechanism of action. J Sex Med 2009, 6(10):2680-2689.
50. Succu S., Sanna F., Cocco C., et al. Oxytocin induces penile erection when injected into the ventral tegmental area of male rats: role of nitric oxide and cyclic GMP. Eur J Neurosci 2008, 28(4):813-821.
51. Tang Y., Rampin O., Calas A., et al. Oxytocinergic and serotonergic innervation of identified lumbosacral nuclei controlling penile erection in the male rat. Neuroscience 1998, 82(1):241-254.
52. Hellstrom W.J. Clinical applications of centrally acting agents in male sexual dysfunction. Int J Impot Res 2008, 20(Suppl 1):S17-S23.
53. Azadzoi K.M., Payton T., Krane R.J., et al. Effects of intracavernosal trazodone hydrochloride: animal and human studies. J Urol 1990, 144(5):1277-1282.
54. Kendirci M., Walls M.M., Hellstrom W.H. Central nervous system agents in the treatment of erectile dysfunction. Urol Clin North Am 2005, 32:487-501.
55. Masand P.S., Ashton A.K., Gupta S., et al. Sustained-release bupropion for selective serotonin reuptake inhibitor-induced sexual dysfunction: a randomized, double-blind, placebo-controlled, parallel-group study. Am J Psychiatry 2001, 158(5):805-807.
56. Safarinejad M.R. The effects of the adjunctive bupropion on male sexual dysfunction induced by a selective serotonin reuptake inhibitor: a double-blind placebo-controlled and randomized study. BJU Int 2010, 106(6):840-847.